Literature DB >> 34081676

Hepatitis C Treatment by Nonspecialist Providers in the Direct-acting Antiviral Era.

Shashi N Kapadia1,2, Phyllis Johnson2, Kristen M Marks1, Bruce R Schackman2, Yuhua Bao2.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) remains under-treated in the United States and treatment by nonspecialist providers can expand access. We compare HCV treatment provision and treatment completion between nonspecialist and specialist providers.
METHODS: This retrospective study used claims data from the Healthcare Cost Institute from 2013 to 2017. We identified providers who prescribed HCV therapy between 2013 and 2017, and patients enrolled in private insurance or Medicare Advantage who had pharmacy claims for HCV treatment. We measured HCV treatment completion, determined based on prescription fills for the minimum expected duration of the antiviral regimen. Using propensity score-weighted regression, we compared the likelihood of early treatment discontinuation by the type of treating provider.
RESULTS: The number of providers prescribing HCV treatment peaked in 2015 and then declined. The majority were gastroenterologists, although the proportion of general medicine providers increased to 17% by 2017. Among the 23,463 patients analyzed, 1008 (4%) discontinued before the expected minimum duration. In the propensity score-weighted analysis, patients treated by general medicine physicians had similar odds of treatment discontinuation compared with those treated by gastroenterologists [odds ratio (OR)=1.00, 95% confidence interval (CI): 0.99-1.01, P=0.45]. Results were similar when comparing gastroenterologists to nonphysician providers (OR=1.00, 95% CI: 0.99-1.01, P=0.53) and infectious diseases specialists (OR=1.00, 95% CI: 0.99-1.01, P=0.71).
CONCLUSIONS: HCV treatment providers remain primarily gastroenterologists, even in the current simplified treatment era. Patients receiving treatment from general medicine or nonphysician providers had a similar likelihood of treatment completion, suggesting that removing barriers to the scale-up of treatment by nonspecialists may help close treatment gaps for hepatitis C.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34081676      PMCID: PMC8384709          DOI: 10.1097/MLR.0000000000001573

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   3.178


  29 in total

1.  Monitoring the hepatitis C care cascade using administrative claims data.

Authors:  Cheryl Isenhour; Susan Hariri; Claudia Vellozzi
Journal:  Am J Manag Care       Date:  2018-05       Impact factor: 2.229

2.  High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.

Authors:  Brianna L Norton; Julia Fleming; Marcus A Bachhuber; Meredith Steinman; Joseph DeLuca; Chinazo O Cunningham; Nirah Johnson; Fabienne Laraque; Alain H Litwin
Journal:  Int J Drug Policy       Date:  2017-08-12

3.  Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity.

Authors:  Shashi N Kapadia; Carrie D Johnston; Kristen M Marks; Bruce R Schackman; Erika G Martin
Journal:  J Public Health Manag Pract       Date:  2019 May/Jun

4.  Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy.

Authors:  Ryan P Westergaard; Lauren J Stockman; Heather A Hyland; Sheila M Guilfoyle; John J Fangman; James M Vergeront
Journal:  J Prim Care Community Health       Date:  2014-11-24

5.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

6.  Discontinuation of new hepatitis C drugs among Medicare patients.

Authors:  Jeah Jung; Ping Du; Roger Feldman; Thomas Riley
Journal:  Am J Manag Care       Date:  2020-02       Impact factor: 2.229

7.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.

Authors:  Czarina N Behrends; Sarah Gutkind; Regan Deming; Kyle R Fluegge; Marie P Bresnahan; Bruce R Schackman
Journal:  J Urban Health       Date:  2021-08       Impact factor: 5.801

8.  Treatment Outcomes of Hepatitis C-Infected Patients in Specialty Clinic vs. Primary Care Physician Clinic: A Comparative Analysis.

Authors:  Taseen Ahmed Syed; Muhammad Hassaan Bashir; Samid Muhammad Farooqui; Allshine Chen; Sixia Chen; Salman Nusrat; Javid Fazili
Journal:  Gastroenterol Res Pract       Date:  2019-06-04       Impact factor: 2.260

9.  Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.

Authors:  Jeah Jung; Ping Du; Roger Feldman; Lan Kong; Thomas Riley
Journal:  J Manag Care Spec Pharm       Date:  2019-11

10.  Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.

Authors:  Marjan Javanbakht; Roxanne Archer; Jeffrey Klausner
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.